[1] A. M. Cueto-Manzabo, S. Konel, V. Crowley, et al., “Bone Hisptopathology and Densitrometry Comparison between Cyclosporine a Monotherapy and Prednisolone Plus Azathioprine Dual Immunosuppression in Renal Transplant Patients,” Transplantation, Vol. 75, No. 12, 2003, pp. 2053-2058. doi:10.1097/01.TP.0000068869.21770.F6
[2] M. Mazzantini, O. Di Munno, L. Sinigaglia, et al., “Effects of Cyclosporine A on Bone Density in Female Rheumatoid Arthritis Patients: Results from a Multicenter Cross-Sectional Study,” Clinical and Experimental Rheumatology, Vol. 25, No. 5, 2007, pp. 700-715.
[3] P. Tannirandorn and S. Epstein, “Drug-Induced Bone Loss,” Osteoporosis International, Vol. 11, No. 8, 2000, pp. 637-659. doi:10.1007/s001980070062
[4] H. M. Frost, “The Biology of Fracture Repair,” Clinical Orthopaedics and Related Research, Vol. 248, 2000, pp. 283-293.
[5] P. Vestergaard, L. Rejnmark and L. Mosekilde, “Methotrexate, Azatioprine, Cyclosporine and Risk of Fracture,” Calcified Tissue International, Vol. 79, No. 2, 2006, pp. 69-75. doi:10.1007/s00223-006-0060-0
[6] M. E. Bolander, “Regulation of Fracture Repair by Growth Factors,” Proceedings of the Society for Experimental Biology and Medicine, Vol. 200, No. 2, 1992, pp. 165170. doi:10.3181/00379727-200-43410A
[7] M. P. G. Bostrom, J. M. Lane, W. S. Berberian, et al., “Immunolocalization and Expression of Bone Morphogenetic Proteins 2 and 4 in Fracture Healing,” Journal of Orthopaedic Research, Vol. 13, No. 3, 1995, pp. 357367. doi:10.1002/jor.1100130309
[8] T. A. Einhorn, “Enhancement of Fracture Healing,” The Journal of Bone & Joint Surgery, Vol. 77, No. 6, 1995, pp. 940-956.
[9] A. Ekelund and O. Nilsson, “Effects of Cyclosporin A on Experimental New Bone Formation in Rats,” Clinical Orthopaedics and Related Research, No. 284, 1992, pp. 288-298.
[10] A. Ekelund and O. Nilsson, “Effects of Cyclosporin A on Bone Turnover and on Resorption of Demineralized Bone Matrix,” Clinical Orthopaedics and Related Research, No. 326, 1996, pp. 127-134. doi:10.1097/00003086-199605000-00015
[11] D. Bunjes, G. Hardt, M. Rollinghoff and H. Wagner, “Cyclosporin A Mediates Immunosuppression of Primary Cytotoxic T Cell Responses by Impairing the Release of Interleukin 1 and Interleukin 2,” European Journal of Immunology, Vol. 11, No. 8, 1981, pp. 657-661. doi:10.1002/eji.1830110812
[12] P. Orcel, J. Bielakoff, D. Modrowski, L. Miravet and M. C. De Vernejoul, “Cyclosporin A Induces in Vivo Inhibition of Resorption and Stimulation of Formation in Rat Bone,” Journal of Bone and Mineral Research, Vol. 4, No. 3, 1989, pp. 387-391. doi:10.1002/eji.1830110812
[13] C. Wada, M. Karaoka, H. Seto, et al., “High-Turnover Osteoporosis Is Induced by Cyclosporin A in Rats,” Journal of Bone and Mineral Metabolism, Vol. 24, No. 3, 2006, pp. 199-205. doi:10.1007/s00774-005-0672-x
[14] G. Movsowitz, S. Epstein, M. Fallon, et al., “Cyclosporin-A in Vivo Produces Severe Osteopenia in the Rat: Effect of Dose and Duration of Administration,” Endocrinology, Vol. 123, No. 5, 1988, pp. 2571-2577. doi:10.1210/endo-123-5-2571
[15] D. Thiebaud, M. A. Krieg, D. Gillard-Berguer, et al., “Cyclosporin Induces High Bone Turnover and May Contribute to Bone Loss after Heart Transplantation,” European Journal of Clinical Investigation, Vol. 26, No. 7, 1996, pp. 549-555. doi:10.1210/endo-123-5-2571
[16] M. Abdelhadi, B. G. Ericzon, K. Hultenby, G. Sjoden, F. P. Reinholt and J. Nordenstrom, “Structural Skeletal Impairment Induced by Immunosupressive Therapy in Rats: Cyclosporine A vs Tacrolimus,” Transplant International, Vol. 15, No. 4, 2002, pp. 180-187. doi:10.1111/j.1432-2277.2002.tb00149.x
[17] T. Ohno, M. Shigetomi, K. Ihara, T. Matsunaga, T. Hashimoto, H. Kawanano, T. Sugiyama and S. Kawai, “Skeletal Reconstruction by Vacularized Allogenic Bone Transplantation: Effects of Statins in Rats,” Transplantation, Vol. 76, No. 5, 2003, pp. 869-871. doi:10.1111/j.1432-2277.2002.tb00149.x
[18] E. Del Pozo and J. Zaff, “Skeletal Growth and Bone Density as Sensitive Parameters in Experimental Arthritis: Effects of Cyclosporin A,” Bone, Vol. 15, No. 6, 1994, pp. 625-628. doi:10.1111/j.1432-2277.2002.tb00149.x
[19] E. Irschik, H. Tilg, D. Niederwieser, G. A. Gastl, et al., “Cyclosporin Blood Levels Do Correlate with Clinical Complications,” Lancet, Vol. 324, No. 8404, 1984, pp. 692-693. doi:10.1111/j.1432-2277.2002.tb00149.x
[20] T. Tsubone, M. Shigetomi, K. Ihara, et al., “Hypertrophy of Vascularized Bone Isografts in Rats Treated with Cyclosporine A,” Calcified Tissue International, Vol. 73, No. 4, 2003, pp. 393-399. doi:10.1111/j.1432-2277.2002.tb00149.x
[21] I. A. Katz, W. S. S. Jee, I. I. Joffe, et al., “Prostaglandin E2 Alleviates Cyclosporin A-Induced Bone Loss in the Rat,” Journal of Bone and Mineral Research, Vol. 7, No. 10, 1992, pp. 1191-1200. doi:10.1111/j.1432-2277.2002.tb00149.x
[22] G. T. Shin, A. Khanna, R. Ding, et al., “In Vivo Expression of Transforming Growth Facto R-Beta 1 in Humans: Stimulation by Cyclosporine,” Transplantation, Vol. 65, No. 3, 1998, pp. 313-318. doi:10.1111/j.1432-2277.2002.tb00149.x
[23] L. Nordsletten, T S. Kaastad, S. Skjeldal, et al., “Fracture Strength Prediction in Rat Femoral Shaft and Neck by Single Photon Absorptiometry of the Femoral Shaft,” Journal of Bone and Mineral Research, Vol. 25, No. 1, 1994, pp. 39-46. doi:10.1111/j.1432-2277.2002.tb00149.x
[24] M. M. Petersen, P. M. Gehrchen, P. K. Nielsen and B. Lund, “Loss of Bone Mineral of the Hip Assessed by DEXA Following Tibial Shaft Fractures,” Bone, Vol. 20, No. 5, 1997, pp. 491-495. doi:10.1111/j.1432-2277.2002.tb00149.x
[25] K. Kawana, M. Takahashi, K. Kushida, et al., “The Effect of Cyclosporin a Administration on Bone Metabolism in the Rat Evaluated by Biomechanical Markers,” Journal of Endocrinological Investigation, Vol. 19, 1996, pp. 499504.